Corbin Capital Partners, L.P. Cytokinetics Inc Transaction History
Corbin Capital Partners, L.P.
- $54.5 Million
- Q4 2024
A detailed history of Corbin Capital Partners, L.P. transactions in Cytokinetics Inc stock. As of the latest transaction made, Corbin Capital Partners, L.P. holds 40,000 shares of CYTK stock, worth $1.45 Million. This represents 16.66% of its overall portfolio holdings.
Number of Shares
40,000Holding current value
$1.45 Million% of portfolio
16.66%Shares
0 transactions
| Quarter | Operation | Price Per share | shares change | shares Held | SEC Form |
|---|
Others Institutions Holding CYTK
# of Institutions
399Shares Held
128MCall Options Held
3.66MPut Options Held
900K-
Black Rock Inc. New York, NY14.7MShares$531 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.8MShares$429 Million0.01% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD9.96MShares$360 Million0.26% of portfolio
-
Wellington Management Group LLP Boston, MA7.99MShares$289 Million0.06% of portfolio
-
State Street Corp Boston, MA6.09MShares$220 Million0.01% of portfolio
About CYTOKINETICS INC
- Ticker CYTK
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 94,144,096
- Market Cap $3.41B
- Description
- Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...